EU Project Combats Emerging Viral Threats with Marburg Virus Research

Unlocking Pandemic Preparedness: A New EU Project Tackles Emerging Viral Threats

Viral disease emergence is accelerating, underscoring the urgent need for robust pandemic preparedness. Beyond saving lives, comprehensive planning protects economies, maintains societal functionality, and bolsters global resilience. The EU’s new COMBINE project is at the forefront of this effort, focusing on the Marburg Virus (MARV) to create a blueprint for identifying antiviral targets against newly emerging viruses.

Coordinated by the German Helmholtz Centre for Infection Research (HZI), COMBINE brings together seven European partners across five countries. Backed by €7.2 million in EU funding over five years, the project aims to advance our understanding of how viruses infiltrate host cells using MARV, a highly pathogenic BSL-4 model virus, as a case study.

The COMBINE approach zeros in on the critical virus-cell binding step, seeking to identify key factors and potential therapeutic targets involved in early viral infections. Professor Christian Sieben, project coordinator and head of the Nanoscale Infection Biology group at HZI, explains, "We’ll combine pioneering approaches to identify the signature of virus-cell activation, characterize binding and entry mechanisms, and develop novel inhibitors and vaccine candidates."

MARV, like Ebola, is a highly infectious and lethal pathogen. It primarily resides in African fruit bats and can transmit between humans. With an incubation period ranging from 2 to 21 days, silent transmission is possible, complicating outbreak control. Recent recurrent outbreaks and the lack of licensed vaccines or specific antivirals heighten the virus’s threat.

Using the COMBINE approach, the team seeks to establish a foundation for the development of specific anti-MARV drugs and optimized vaccines. Sieben emphasizes, "Our goal is to significantly reduce premature mortality and healthcare burdens caused by the Marburg virus. But our work will also fortify global virology, boost pandemic preparedness, and strengthen health security against emerging viral diseases."

Beyond=float: rigidity raza:: Marburg virus insights, COMBINE is creating an innovative pipeline to identify and target proteins involved in virus attachment. This versatile blueprint will facilitate cross-country collaborations, enabling rapid development of drugs and vaccines against emerging viruses. By expanding our knowledge of MARV cell entry and establishing a technology pipeline, COMBINE is arming the global health community against future pandemics.

Project Partners:

• Belgium: Vlaams Instituut voor Biotechnologie (VIB)
• Germany: European Research and Project Office GmbH (EURICE), Helmholtz Centre for Infection Research (HZI), University of Marburg (UMR)
• Norway: University of Oslo, Faculty of Medicine
• Romania: Institute of Biochemistry of the Romanian Academy (IBRA)
• Sweden: Karolinska Institutet (KI)

The COMBINE project represents a crucial step forward⁣ in the global fight against emerging viral threats. By ⁤focusing on MARV, a highly pathogenic virus, COMBINE aims to establish a powerful framework for rapid identification of antiviral targets applicable to a broad spectrum of viruses. This ⁢innovative, collaborative approach, driven by European expertise and innovation, holds immense potential to not only mitigate the ‍devastating impact of future outbreaks, but also to strengthen global pandemic preparedness. The lessons learned and the tools developed through COMBINE will ‍serve as invaluable assets in safeguarding public‍ health, bolstering economic stability,⁢ and ensuring ⁢a more resilient future for ‍all.
in a world facing an escalating threat of emerging viral diseases, the COMBINE project offers a beacon of hope. By focusing on MARV, this ambitious EU initiative not only seeks to understand the intricacies of viral pathogenesis but also to develop innovative strategies for combating future outbreaks. The success of COMBINE could pave the way for a paradigm shift in pandemic preparedness, equipping us with the tools to effectively neutralize emerging viral threats and safeguard global health security. As the project progresses, the world watches with anticipation, hopeful that the knowledge gained will translate into life-saving interventions, ultimately ushering in a future where we are better prepared to face the challenges posed by infectious diseases.